EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC 4.0

Ruxolitinib-Treated Myeloproliferative Neoplasms: Real-World Infectious Outcomes and Preventive Practices from a Single Center

Muruvvet Seda Aydin, Gülten Korkmaz, Merve Pamukcuoglu, Hatice Rahmet Guner, Funda Ceran, Simten Dagdas, Gulsum Ozet

Mediterranean Journal of Hematology and Infectious Diseases · 30.04.2026 · 18 (1) · e2026044

DOI: 10.4084/mjhid.2026.044 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Mediterranean Journal of Hematology and Infectious Diseases, online erschienen am 30.04.2026. Verfasst von Muruvvet Seda Aydin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Ankara Bilkent City Hospital, Ankara, Turkiye. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ruxolitinib has been associated with an increased risk of viral infections and tuberculosis reactivation in patients with Philadelphia chromosome-negative myeloproliferative neoplasm. However, data regarding screening practices and prophylactic approaches in routine clinical care remain limited.

Objective

To describe latent tuberculosis screening, antiviral prophylaxis practices, and infectious outcomes in ruxolitinib-treated patients with myeloproliferative neoplasm at a single center.

Methods

Thirty patients with Philadelphia chromosome-negative myeloproliferative neoplasm treated with ruxolitinib were included in this retrospective single-center study.

Results

The median duration of ruxolitinib therapy was 20.1 months. Latent tuberculosis screening was performed in nearly all patients, and isoniazid prophylaxis was administered to five individuals according to screening results. No tuberculosis reactivation occurred during follow-up. Antiviral prophylaxis was administered to 56.6% of patients. One patient developed herpes zoster during treatment, and two experienced recurrent oral herpes. Exploratory analyses did not identify statistically significant clinical factors associated with recurrent oral herpes or antiviral prophylaxis initiation.

Conclusion

This study provides a descriptive real-world account of infectious outcomes and institutional screening and management practices in ruxolitinib-treated patients with Philadelphia chromosome-negative myeloproliferative neoplasm. Larger prospective studies are required to further clarify optimal screening and prophylactic strategies.

Schlagwörter

Stichwörter der Autor:innen

Herpes simplexHerpes zosterLatent tuberculosisProphylaxisRuxolitinib

Autor:innen und Institutionen

  • Department of Hematology, Ankara Bilkent City Hospital, Ankara, Turkiye.
  • Department of Infectious Diseases, Ankara Bilkent City Hospital, Ankara, Turkiye.

Zitieren

APA

Aydin, M. S., Korkmaz, G., Pamukcuoglu, M., Guner, H. R., Ceran, F., Dagdas, S., & Ozet, G. (2026). Ruxolitinib-Treated Myeloproliferative Neoplasms: Real-World Infectious Outcomes and Preventive Practices from a Single Center. Mediterranean Journal of Hematology and Infectious Diseases, 18(1), e2026044. https://doi.org/10.4084/mjhid.2026.044

Vancouver

Aydin MS, Korkmaz G, Pamukcuoglu M, Guner HR, Ceran F, Dagdas S, et al. Ruxolitinib-Treated Myeloproliferative Neoplasms: Real-World Infectious Outcomes and Preventive Practices from a Single Center. Mediterranean Journal of Hematology and Infectious Diseases. 2026;18(1):e2026044. doi:10.4084/mjhid.2026.044

BibTeX
@article{Aydin2026,
  author = {Aydin, Muruvvet Seda and Korkmaz, Gülten and Pamukcuoglu, Merve and Guner, Hatice Rahmet and Ceran, Funda and Dagdas, Simten and Ozet, Gulsum},
  title = {Ruxolitinib-Treated Myeloproliferative Neoplasms: Real-World Infectious Outcomes and Preventive Practices from a Single Center},
  journal = {Mediterranean Journal of Hematology and Infectious Diseases},
  year = {2026},
  volume = {18},
  number = {1},
  pages = {e2026044},
  doi = {10.4084/mjhid.2026.044}
}
Kostenlos starten →